The United Kingdom and the United States have reached a landmark trade agreement that will keep no duties on British medicine shipments entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to increase funding on pharmaceuticals through the public health system. This pledge guarantees that duties on these crucial products will remain at zero for a timeframe of the next three years.
This agreement comes after recent threats to dramatically increase import taxes on branded pharmaceutical products, with potential rates discussed as high as 100%.
"This deal with the Britain bolsters the international landscape for new treatments and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's most significant exports to the America, which is by far the largest market for large British pharmaceutical firms.
Export figures reveal that in the one-year period prior to last September, the UK sold drugs valued at £11.1bn to the US. This amount accounted for 17.4% of British export trade in that period.
"This guarantee protects jobs, increases funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," a minister commented.
Key British Pledges
The agreement includes several notable changes from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds exceeded twenty percent.
Recent Tensions
The pact takes place against a long-running tension between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were exacerbated by claims that American consumers were charged a premium for the equivalent treatments than people in the other developed nations.
In recent months, several major drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been announced toward US facilities.
One official stated that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
